From a friend:
"First of all, I do not use the term IDCP and do not treat patients with it differently. There is significant histological heterogeneity among mCRPC patients both at autopsy and in biopsy studies. However in a given patient non matter what the histology, there usually remain clones of the cancer that are AR driven and AR independent. In the future we may have a way to quantitate the ratio but not currently. Therefore we continue AR inhibition with Lupron in all mCRPC while adding agents that are either AR inhibiting (abi,enza etc) or non AR inhibiting (radium, Provenge, chemo). I cannot speak to this patient specifically (Not you Hilander) but he seems to have an AR independent pr
opensity. Moreover he probably had mets at the time of diagnosis. Therefore LHRHa should continue and non AR directed therapy should be added. Hope this helps"
Post Edited (Tony Crispino) : 3/21/2016 12:02:40 AM (GMT-6)